Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

Seetal DoddSchool of Medicine, Barwon Health, Deakin University, IMPACT SRC (Innovation in Mental and Physical Health and Clinical Treatment – Strategic Research Centre), Geelong, Australia; ;Department of Psychiatry, University of Melbourne, Melbourne, Australia; ;Mental Health Drug and Alcohol Services, University Hospital Geelong, Barwon Health, Geelong, Australia; ;Orygen The National Centre of Excellence in Youth Mental Health, Parkville, Australia; Correspondence[email protected]

Philip B. MitchellSchool of Psychiatry, University of New South Wales, and Black Dog Institute, Sydney, Australia;

Michael BauerDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische, Universität Dresden, Dresden, Germany;

Lakshmi YathamDepartment of Psychiatry, University of British Columbia, British Columbia, BC, Canada;

Allan H. YoungDepartment of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK & South London and Maudsley NHS Foundation Trust, London, UK;

Sidney H. KennedyDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada;

Lana WilliamsSchool of Medicine, Barwon Health, Deakin University, IMPACT SRC (Innovation in Mental and Physical Health and Clinical Treatment – Strategic Research Centre), Geelong, Australia;

Trisha SuppesDepartment of Psychiatry & Behavioral Sciences, School of Medicine, Stanford University, Stanford, CA, USA;

Carlos Lopez JaramilloDepartment of Psychiatry, Universidad de Antioquia, Medellín, Colombia;

Madhukar H. TrivediDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA;

Maurizio FavaDivision of Clinical Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA;

A. John RushDuke-National University of Singapore Medical School, Singapore, Singapore;

Roger S. McIntyreDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada; ;Mood Disorders Psychopharmacology Unit, University of Toronto, Toronto, ON, Canada; ;Brain and Cognition Discovery Foundation, Toronto, ON, Canada;

Michael E. ThaseDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA;

Raymond W. LamDepartment of Psychiatry, University of British Columbia, British Columbia, BC, Canada;

Emanuel SeverusDepartment of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische, Universität Dresden, Dresden, Germany;

Siegfried KasperDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Wien, Austria

Michael BerkSchool of Medicine, Barwon Health, Deakin University, IMPACT SRC (Innovation in Mental and Physical Health and Clinical Treatment – Strategic Research Centre), Geelong, Australia; ;Department of Psychiatry, University of Melbourne, Melbourne, Australia; ;Mental Health Drug and Alcohol Services, University Hospital Geelong, Barwon Health, Geelong, Australia; ;Orygen The National Centre of Excellence in Youth Mental Health, Parkville, Australia; ;The Florey Institute of Neuroscience and Mental Health, Parkville, Australia;

show all

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date